bioAffinity Technologies, Inc. (BIAF): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$9.39M

Year ended 2025-12-31

-$11.56M

Trailing 12 months to 2026-06-30

2022-12-31 Free Cash Flow (USD) 2025-12-31

Period ended	Free Cash Flow	Change YoY	Source filing
2025-12-31	-$9.39M	n/m	2026-03-16, From 2025-01-01
2024-12-31	-$7.34M	n/m	2026-03-16, From 2024-01-01
2023-12-31	-$6.06M	n/m	2025-03-31, From 2023-01-01
2022-12-31	-$4.29M	n/a	2024-04-01, From 2022-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Free Cash Flow	Change YoY
bioAffinity Technologies, Inc. (BIAF)	2025-12-31	-$9.39M	n/m
Absci Corp (ABSI)	2025-12-31	-$94.03M	n/m
Foxo Technologies Inc. (FOXO)	2025-12-31	-$3.93M	n/a
OmniAb, Inc. (OABI)	2025-12-31	-$37.02M	n/m
iSpecimen Inc. (ISPC)	2025-12-31	-$4.24M	n/m
OneMedNet Corp (ONMD)	2025-12-31	-$7.52M	n/m
MaxCyte, Inc. (MXCT)	2025-12-31	-$36.18M	n/m
NRC Health (NRC)	2025-12-31	$15.74M	-17.9%
Medpace Holdings, Inc. (MEDP)	2025-12-31	$681.87M	+19.2%

Compare BIAF, ABSI, FOXO, OABI side by side · Screen every company in Services-Commercial Physical & Biological Research ↗